SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
LONG-TERM OUTCOMES AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) BY RESPONSE
STATUS FOR BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) ± DARATUMUMAB IN
DISCLOSURES POSTER 38
ALCYONE
Paula Rodriguez-Otero1, Mario Boccadoro2, Roman Hajek3, Tomoaki Fujisaki4, Jae Hoon Lee5, Joaquin
Martinez-Lopez6, Paulo Lucio7, Zsolt Nagy8, Ganna Usenko9, Anna Marina Liberati10, Mihaela Cornelia
Lazaroiu11, Dariusz Woszczyk12, Hiroyuki Takamatsu13, Joanna Romejko-Jarosinska14, Stefan Knop15,
Astrid Pavlovsky16, Cecily Forsyth17, Takayuki Ishikawa18, Katharine S. Gries19, Huiling Pei20, Anupa
Kudva21, Jon Ukropec22, Susan Wroblewski23, Robin Carson24 and Meletios A. Dimopoulos25
(1)Clínica Universidad de Navarra, Pamplona, Spain
(2)Division of Hematology - Department of Molecular Biotechnology and Health Sciences - University
of Torino, Torino, Italy
(3)Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
(4)Matsuyama Red Cross Hospital, Matsuyama, Japan
(5)Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea,
Republic of (South)
(6)Hospital 12 de Octubre, H12O-CNIO, Haematological Malignancies Clinical Research Unit,
Universidad Complutense, CIBERONC, Madrid, Spain
(7)Champalimaud Centre for the Unknown, Lisbon, Portugal
(8)1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary
(9)Head of City Hematology Center, City Clinical Hospital #4, Hematology Center, Dnepropetrovsk,
Ukraine
(10)Azienda Ospedaliera "Santa Maria", Terni, Italy
(11)Policlinica de Diagnostic Rapid Brasov, Brasov, Romania
(12)Hematology Department, University of Opole, Opole, Poland
(13)Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health
Sciences, Kanazawa University, Kanazawa, Japan
(14)Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(15)Würzburg University Medical Center, Würzburg, Germany
(16)Fundaleu, Buenos Aires, Argentina
(17)Gosford Hospital, Gosford, NSW, Australia
(18)Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
(19)Janssen Global Services, LLC, Raritan, NJ
(20)Janssen Research & Development, LLC, Titusville, NJ
(21)Janssen Research & Development, LLC, Raritan, NJ
(22)Janssen Global Medical Affairs, Horsham, PA
(23)Janssen Research & Development, Spring House, PA
(24)Janssen Research & Development, LLC, Spring House, PA
(25)National and Kapodistrian University of Athens, Athens, Greece
Objective: In phase 3 ALCYONE, daratumumab, a human IgGκ CD38-targeting monoclonal antibody,
with VMP (D-VMP) reduced the risk of disease progression/death by 58% vs VMP alone (median
progression-free survival PFS, 36.4 vs 19.3 months; P<0.0001) and demonstrated significant overall
survival (OS) benefit (P=0.0003) for patients with transplant-ineligible newly diagnosed multiple
myeloma (TIE NDMM). Results of subgroup analyses examining long-term efficacy and HRQoL
outcomes by response status are reported.
Methods: Patients were randomly assigned 1:1 to receive up to nine 6-week cycles of VMP (V: 1.3
mg/m2 subcutaneous; M: 9 mg/m2 oral; P: 60 mg/m2 oral ) ± daratumumab (16 mg/kg intravenous).